Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials
Langue
EN
Article de revue
Ce document a été publié dans
npj Precision Oncology. 2024-10-07, vol. 8, n° 1, p. 227
Résumé en anglais
Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients ...Lire la suite >
Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.< Réduire
Unités de recherche